CN113368132A - Liquid dressing for treating psoriasis - Google Patents

Liquid dressing for treating psoriasis Download PDF

Info

Publication number
CN113368132A
CN113368132A CN202110662447.5A CN202110662447A CN113368132A CN 113368132 A CN113368132 A CN 113368132A CN 202110662447 A CN202110662447 A CN 202110662447A CN 113368132 A CN113368132 A CN 113368132A
Authority
CN
China
Prior art keywords
parts
zinc
film
liquid dressing
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN202110662447.5A
Other languages
Chinese (zh)
Inventor
李俊锋
胡波
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Yiyaotong Pharmaceutical Co ltd
Original Assignee
Guangzhou Yiyaotong Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Yiyaotong Pharmaceutical Co ltd filed Critical Guangzhou Yiyaotong Pharmaceutical Co ltd
Priority to CN202110662447.5A priority Critical patent/CN113368132A/en
Publication of CN113368132A publication Critical patent/CN113368132A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • A61K31/055Phenols the aromatic ring being substituted by halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/30Zinc; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007Drug-containing films, membranes or sheets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0004Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing inorganic materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0014Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061Use of materials characterised by their function or physical properties
    • A61L26/0066Medicaments; Biocides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A61L2300/102Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/204Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/216Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/402Anaestetics, analgesics, e.g. lidocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404Biocides, antimicrobial agents, antiseptic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention belongs to the technical field of medicines, and particularly discloses a liquid dressing for treating psoriasis, which comprises zinc pyrithione, zinc oxide, zinc-containing mineral substances, menthol, ethanol, borneol, parachlorometaxylenol, a film-forming agent, a film-forming auxiliary agent and purified water containing selenium. The synergistic effect of the components can obviously enhance the treatment effect on skin diseases such as psoriasis and the like and reduce the irritation to the skin, has the effects of relieving itching and easing pain, can effectively relieve the symptoms of patients, simultaneously enhances the stability of a raw material system in a film forming mode, can isolate oxygen in the air, stops the growth and reproduction of pathogenic bacteria, forms a grid shape on the surface of the skin of the protective film, and is beneficial to normal skin growth and repair.

Description

Liquid dressing for treating psoriasis
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a liquid dressing for treating psoriasis.
Background
Today, some intractable skin diseases are still difficult to be eradicated completely in the case of the rapid development of modern medicine. The skin diseases are caused by a plurality of reasons, and the skin diseases are caused by daily bad living habits except family inheritance. Most patients belong to allergic constitution, and abnormal secretion of endocrine system and gastrointestinal digestive system of the patients may cause skin diseases with the increase of age. The disease probability can be increased in living environment with strong sunlight, and high humidity or dryness. Bad living habits can also cause skin diseases, such as frequent use of irritant skin care products, excessive use of facial cleanser and the like, which can damage skin cell tissues on the surface of a human body, cause the fragility of an epidermal tissue system and cannot resist the invasion of external pathogenic bacteria, thus causing a large amount of flora to be parasitic on the surface of the skin, and further inducing the generation of the skin diseases. The clinical symptoms of the disease are manifested by pruritus, patients can not endure the pruritus and buckle the skin, the cuticle of the skin is thinned, the ulceration infection of the focus area is easily caused, the focus area is further expanded, and the recurrence rate is very high.
At present, antifungal medicines, such as antibiotics, glucocorticoids, tretinoin and the like, are adopted to treat skin diseases such as tinea capitis, seborrheic dermatitis, pityriasis capitis and the like, but long-term use of the antibiotic medicines can easily cause drug resistance of human bodies, long-term use of the glucocorticoids can cause great harm to the human bodies due to Cushing's syndrome, and although a plurality of medical apparatus products for treating the skin diseases exist in the market, the treatment effects are different, the better treatment effect is difficult to achieve, and the problem of easy relapse exists after the skin diseases are cured, so that the invention of a treatment product with good treatment effect on the skin diseases and capable of effectively reducing the relapse rate is urgently needed.
Patent document CN105709273A discloses a liquid medical adjuvant containing polyethylene glycol, which aims to provide a multifunctional medical liquid dressing for promoting wound healing, and is technically characterized by containing polyethylene glycol 400, zinc pyrithione, glycerol, menthol and the balance of propylene glycol. The zinc pyrithione can effectively inhibit excessive proliferation of epidermoid epigastric cells, has a bacteriostatic action, can relieve inflammatory reaction at skin lesions, relieves pruritus and pain at the skin lesions, has a synergistic effect when being combined with polyethylene glycol and menthol, enhances the anti-inflammatory, itching relieving and pain relieving effects of the menthol, is used for superficial wounds (superficial dermis and wounds above the superficial dermis) of human body surfaces, can form a protective film on the wounds, protects the wounds, provides a healing environment for the wounds, has the effects of bacteriostasis, lubrication, moisture preservation, dry crack prevention, cooling, itching relieving and infection inhibition, but has certain irritation on skin and the problem of easy relapse.
Patent document CN105412731A discloses an ointment for treating cutaneous pruritus, which is prepared from the following raw materials: the traditional Chinese medicine composition is prepared from phellodendron, glabrous greenbrier rhizome, black snake meat, manyleaf paris rhizome, cicada slough, raw fleece-flower root, raw rhubarb, rhizoma atractylodis, natural indigo, honeysuckle, cortex dictamni, motherwort herb, astragalus, camellia oil, chamomile essential oil, propyl p-hydroxybenzoate, polyoxyethylene fatty acid ester, zinc pyrithione, ammonium glycyrrhizinate, diethanolamide and salicylic acid, can better treat skin pruritus caused by allergic dermatitis, eczema, urticaria, dermatophytosis and the like, has obvious curative effect and quick response, can treat both symptoms and root causes, has no toxic or side effect through clinical verification, is simple and easy to operate in preparation process, easily available in raw materials, does not have adverse reaction, and has the problem of incomplete treatment and easy recurrence.
Through search, the composition containing zinc pyrithione, zinc oxide and mineral substances and the application of the composition in medical liquid dressing for treating psoriasis are not discovered at present.
Disclosure of Invention
The invention aims to provide a liquid dressing for treating psoriasis, which can effectively treat the psoriasis, has better stability, has no irritation to skin and can effectively reduce the recurrence rate of skin diseases such as the psoriasis and the like.
In order to achieve the purpose, the invention adopts the following technical scheme: a liquid dressing for treating psoriasis comprises the following raw materials in parts by weight: 1.0-5.0 parts of zinc pyrithione, 1.0-3.0 parts of zinc oxide, 1.0-6.0 parts of zinc-containing mineral substance, 0.1-1.0 part of menthol, 1.0-3.0 parts of ethanol, 0.1-1.0 part of borneol, 0.5-2.0 parts of parachlorometaxylenol, 10.0-20.0 parts of film-forming agent, 1.0-5.0 parts of film-forming assistant and 54.0-84.3 parts of purified water containing selenium
Preferably, the feed comprises the following raw materials in parts by weight: 3.0 parts of zinc pyrithione, 6.0 parts of zinc oxide, 1.5 parts of zinc-containing mineral substances, 0.5 part of menthol, 2.0 parts of ethanol, 0.5 part of borneol, 1.0 part of parachlorometaxylenol, 15.0 parts of film-forming agent, 3.0 parts of film-forming assistant and 67.0 parts of purified water containing selenium.
Preferably, the zinc-containing minerals include zinc carbonate, zinc sulfate, zinc oxide, and zinc chloride.
Preferably, the film former is prepared from polyvinyl alcohol and polyvinylpyrrolidone in a ratio of 1: 2 in mass ratio.
Preferably, the coalescing agent is arachidyl glucoside.
Preferably, the weight part ratio of the zinc pyrithione to the zinc-containing mineral is 1 (2-4).
In addition, a preparation method of the liquid dressing for treating psoriasis is also disclosed, and comprises the following steps:
s1, weighing polyvinylpyrrolidone with a formula amount and selenium-containing water with a formula amount of 1/5, purifying, mixing, putting into a water bath heating pot, heating in a water bath, and fully dissolving until no granular sensation exists, thus obtaining polyvinylpyrrolidone solution;
s2, placing the rest selenium-containing purified water in a stirring pot, heating, adding zinc pyrithione, zinc oxide, zinc-containing mineral substances, polyvinyl alcohol, arachidyl glucoside, menthol, ethanol, borneol and parachlorometaxylenol in the formula amount, and stirring fully for later use;
s3, transferring the polyvinylpyrrolidone solution prepared in the step S1 to the stirrer in the step S2, fully stirring, and filling the finally obtained solution to obtain the required liquid dressing.
Preferably, the selenium-containing purified water in the step S2 is heated to 40-60 ℃.
Compared with the prior art, the invention has the following beneficial effects:
(1) through the synergistic effect of the zinc pyrithione and the traditional Chinese medicine composition, the invention can obviously enhance the effects of inhibiting the growth of fungi, relieving itching and easing pain of the product, effectively reduce the irritation of the raw material components to the skin and simultaneously effectively reduce the recurrence rate of skin diseases such as psoriasis and the like.
(2) The invention enhances the stability of the raw material system in the form of film formation, can isolate oxygen in the air, can stop the oxygen for the growth and the propagation of germs, and can form a grid shape on the surface of the skin by the protective film, thereby being beneficial to the growth and the repair of normal skin.
Detailed Description
The present invention will be further described below by way of specific embodiments, but the present invention is not limited to only the following examples. It will be apparent to those skilled in the art that the invention can be modified and replaced with other components having the same effects without departing from the spirit and scope of the invention, and all such modifications and substitutions are deemed to be within the scope of the invention.
The raw materials used in the invention are all conventional commercial products.
In the embodiment of the invention, the preparation method of the selenium-containing purified water comprises the following steps:
taking raw water suitable for spring warm water, firstly pressurizing the raw water by a raw water booster pump, then sequentially filtering the raw water by a multi-medium filter and an activated carbon filter for multiple times, carrying out ion exchange on the filtered purified water by an ion exchanger, then filtering, carrying out reverse osmosis and distillation by a security filter, a multi-stage high-pressure pump and an RO reverse osmosis system to complete further purification of the purified water, and finally sterilizing and filling the purified water to obtain the selenium-containing purified water required by the invention.
Example 1A liquid dressing for the treatment of psoriasis
The formula is as follows: 100g of zinc pyrithione, 100g of zinc oxide, 300g of zinc-containing mineral, 10g of menthol, 100g of ethanol, 10g of borneol, 50g of parachlorometaxylenol, 800g of polyvinylpyrrolidone, 400g of polyvinyl alcohol, 100g of arachidonol glucoside and 8030g of purified water containing selenium.
The preparation method comprises the following steps:
s1, weighing polyvinylpyrrolidone with a formula amount and selenium-containing water with a formula amount of 1/5, purifying, mixing, putting into a water bath heating pot, heating in a water bath, and fully dissolving until no granular sensation exists, thus obtaining polyvinylpyrrolidone solution;
s2, placing the residual selenium-containing purified water in a stirring pot, heating to 40 ℃, adding zinc pyrithione, zinc oxide, zinc-containing mineral substances, polyvinyl alcohol, arachidonol glucoside, menthol, ethanol, borneol and parachlorometaxylenol in the formula, and fully stirring for later use;
s3, transferring the polyvinylpyrrolidone solution prepared in the step S1 to the stirrer in the step S2, fully stirring, and filling the finally obtained solution to obtain the required liquid dressing.
Example 2A liquid dressing for the treatment of psoriasis
The formula is as follows: 300g of zinc pyrithione, 200g of zinc oxide, 600g of zinc-containing mineral, 50g of menthol, 200g of ethanol, 50g of borneol, 100g of parachlorometaxylenol, 1000g of polyvinylpyrrolidone, 500g of polyvinyl alcohol, 300g of arachidonol glucoside and 6700g of purified water containing selenium.
The preparation method comprises the following steps:
s1, weighing polyvinylpyrrolidone with a formula amount and selenium-containing water with a formula amount of 1/5, purifying, mixing, putting into a water bath heating pot, heating in a water bath, and fully dissolving until no granular sensation exists, thus obtaining polyvinylpyrrolidone solution;
s2, placing the rest selenium-containing purified water in a stirring pot, heating to 50 ℃, adding zinc pyrithione, zinc oxide, zinc-containing mineral, polyvinyl alcohol, arachidonol glucoside, menthol, ethanol, borneol and parachlorometaxylenol in the formula, and fully stirring for later use;
s3, transferring the polyvinylpyrrolidone solution prepared in the step S1 to the stirrer in the step S2, fully stirring, and filling the finally obtained solution to obtain the required liquid dressing.
Example 3A liquid dressing for the treatment of psoriasis
The formula is as follows: 300g of zinc pyrithione, 300g of zinc oxide, 600g of zinc-containing mineral, 100g of menthol, 300g of ethanol, 100g of borneol, 200g of parachlorometaxylenol, 1200g of polyvinylpyrrolidone, 600g of polyvinyl alcohol, 500g of arachidonol glucoside and 5800g of purified water containing selenium.
The preparation method comprises the following steps:
s1, weighing polyvinylpyrrolidone with a formula amount and selenium-containing water with a formula amount of 1/5, purifying, mixing, putting into a water bath heating pot, heating in a water bath, and fully dissolving until no granular sensation exists, thus obtaining polyvinylpyrrolidone solution;
s2, placing the residual selenium-containing purified water in a stirring pot, heating to 60 ℃, adding zinc pyrithione, zinc oxide, zinc-containing mineral substances, polyvinyl alcohol, arachidonol glucoside, menthol, ethanol, borneol and parachlorometaxylenol in the formula, and fully stirring for later use;
s3, transferring the polyvinylpyrrolidone solution prepared in the step S1 to the stirrer in the step S2, fully stirring, and filling the finally obtained solution to obtain the required liquid dressing.
Comparative example 1a liquid dressing for the treatment of psoriasis
The comparative example differs from example 2 only in that: no zinc pyrithione is contained.
The preparation method refers to example 2.
Comparative example 2 a liquid dressing for the treatment of psoriasis
The comparative example differs from example 2 only in that: contains no zinc-containing minerals.
The preparation method refers to example 2.
Comparative example 3a liquid dressing for the treatment of psoriasis
The comparative example differs from example 2 only in that: contains no arachidyl glucoside.
The preparation method refers to example 2.
Comparative example 4 a liquid dressing for the treatment of psoriasis
The comparative example differs from example 2 only in that: propylene glycol was used in place of arachidonol glucoside.
The preparation method refers to example 2.
Test example one, psoriasis treatment effect test of liquid dressing
Firstly, experimental samples: liquid dressings were prepared in examples 1 to 3 and comparative examples 1 to 2.
Second, Experimental methods
2.1 establishment of psoriasis model in mice
The mice are raised in a clean environment, the temperature is 22 +/-2 ℃, the relative humidity is 40-60%, and the illumination time is controlled to be 14 h. The experiment was started after 1 week of adaptation. 104 mice were randomly divided into a normal control group, a model control group, and a methotrexate group (positive control group), examples 1 to 3, and comparative examples 1 to 2, and 13 mice were each group. The back hair of each group of mice is removed by 4cm2The normal control group was topically applied with petrolatum only, and the remaining groups of mice were applied with imiquimod cream 10mg each time, 2 times daily for 14 days continuously. At the same time of molding, the experimental group is respectively smeared with the liquid dressings prepared in examples 1-3 and comparative examples 1-2, 1.0ml of the liquid dressings is used each time, methotrexate 2.5mg/kg is given to a positive control group, and the mice of a normal control group and a model control group are smeared with physiological saline with the same volume for 1 time every day and are continuously administrated for 14 days.
2.2 evaluation of mouse skin lesion Change on psoriasis-like skin lesion area and disease severity (PASI) score
The skin damage condition of the mice is observed every day and recorded by a camera, and the erythema, phosphorus chips and infiltration thickening degree of the skin damage of the mice are given 0-4 points according to the PASI scoring standard, wherein the standard is as follows. 0: none; 1: mild; 2, moderate; 3: (ii) severe; 4: the mouse is extremely severe, the integration of the three is added to obtain a total score, and the integration of each group of mice is averaged.
Third, experimental results
The experimental results are shown in tables 1 to 4.
After the imiquimod is smeared for 7 days, obvious erythema appears on the skin of each group of mice, the skin is continuously thickened and resembles psoriasis-like skin lesions, and the psoriasis symptoms are aggravated after the imiquimod is smeared for 14 days.
TABLE 1 Effect of liquid dressings on skin hypertrophy Scoring of psoriasis mice
Figure BDA0003115646020000061
Note that P <0.01 in comparison with normal control group
TABLE 2 Effect of liquid dressings on skin Scale Scoring in psoriatic mice
Figure BDA0003115646020000062
Note that P <0.01 in comparison with normal control group
TABLE 3 Effect of liquid dressings on skin erythema score in psoriasis mice
Figure BDA0003115646020000071
Note that P <0.01 in comparison with normal control group
TABLE 4 Total score results for area of psoriatic lesions and disease severity in the backs of mice
Figure BDA0003115646020000072
Note that P <0.0 in comparison with the normal control group
From the data in tables 1 to 4, it can be known that the mice in the groups of examples 1 to 3 of the present invention have lighter erythema, less scales, and slight thickening and swelling degree; the data of the embodiments 1-3 groups and the model group can be used for obtaining that the liquid dressing prepared by the invention can remarkably relieve the corresponding symptoms of the psoriasis mouse; the data of the groups of examples 1-3 and the groups of comparative examples 1-2 show that the synergistic effect between the zinc pyrithione and the zinc-containing mineral matter can effectively treat psoriasis, and can reduce the irritation of the raw material components such as the zinc pyrithione to the skin.
Test example II Long-term storage stability test
Firstly, experimental samples: the liquid dressings prepared in examples 1 to 3 and comparative examples 3 to 4.
Second, Experimental methods
The liquid dressings prepared in examples 1-3 and comparative examples 3-4 were stored at room temperature of 25 ℃. + -. 5 ℃ for 12 months, and were taken out at 0, 3, 6, 9, and 12 months, and the spreading condition of the sample and the filming condition of the sample after 12 months of storage were observed.
The scoring criteria are shown in table 5.
TABLE 5 liquid dressing spreadability Scoring standards
Figure BDA0003115646020000081
Third, experimental results
The experimental results are shown in tables 6 to 7.
TABLE 6 Long-term storage stability test results
Figure BDA0003115646020000082
TABLE 7 results of film formation at month 12 of the samples
Figure BDA0003115646020000083
Figure BDA0003115646020000091
As can be seen from table 6, the liquid dressings prepared in examples 1 to 3 of the present invention are easy to apply when used, and still have good applicability after being left for 3 months, 6 months, 9 months, and 12 months, and the liquid dressings prepared in examples 1 to 3 have gradually deteriorated applicability as the leaving time is prolonged, thereby proving that the addition of arachidonoyl glucoside of the present invention can significantly improve the applicability of the liquid dressings, and enhance the stability of the liquid dressings.
As can be seen from table 7, the liquid dressings prepared in examples 1 to 3 of the present invention still had a rapid film formation after moisture evaporation and maintained good stability after being left for 12 months, while the liquid dressings prepared in comparative examples 3 to 4 lacked arachidonoyl glucoside, and therefore, after being left for 12 months, the samples agglomerated and accumulated after moisture evaporation, and a film was hardly formed.
The experimental results show that the liquid dressing prepared in the embodiments 1 to 3 of the present invention can be uniformly applied, and the faster film forming property is probably because the hydroxyl groups in the structures of the polyvinyl alcohol and the arachidyl glucoside can form hydrogen bonds with the carbonyl group of the polyvinylpyrrolidone, so that the stability of the formed reticular film structure is enhanced, and the treatment effect of the liquid dressing on psoriasis is further ensured.
Test example three, evaluation of therapeutic effect of liquid dressing and evaluation of psoriasis recurrence suppressing effect
Firstly, experimental samples: liquid dressing of examples 1 to 3
Second, the tested population
Skin condition: the psoriasis patients are healthy, only have obvious erythema, have no history of skin allergy, and meet the voluntary selection standard of the subjects.
Grouping: divided into 3 groups of 50, 23 women and 27 men.
The test method comprises the following steps: the medicine is uniformly coated on the skin damage area 1 time per day, the phenomenon that eyes and other mucous membrane parts are contacted with the medicine is strictly avoided, the trial is carried out for 1 month, and the testee keeps good living and rest time and eating habits during the trial period. The feedback condition of the subjects was counted after 1 month, and the subjects were followed up half a year after the experiment, and the psoriasis recurrence condition of the subjects of examples 1-3 was counted.
Third, experimental results
The experimental results are shown in tables 8 to 10.
Table 8 test results for the liquid dressing of example 1
Figure BDA0003115646020000092
Table 9 test results for liquid dressing of example 2
Figure BDA0003115646020000101
Table 10 test results for example 3 liquid dressing
Figure BDA0003115646020000102
From tables 8 to 10, the liquid dressings of examples 1 to 3 of the present invention were approved by most subjects, had a good effect of treating psoriasis, and were effective in relieving itching and pain, and among them, the liquid dressing of example 1 had the highest approval.
From the data of psoriasis recurrence in the subject after the follow-up of the table for half a year, it can be known that the liquid dressing of the present invention has a low psoriasis recurrence rate, i.e. the present invention can effectively inhibit the recurrence after the psoriasis is cured. All subjects do not have adverse reactions such as allergy, red swelling and the like in the test of various projects.
The synergistic effect of the zinc pyrithione and the zinc-containing mineral substance can obviously enhance the treatment effect on skin diseases such as psoriasis and the like, has the effect of relieving itching and easing pain and can effectively relieve the pain of patients, and simultaneously, the zinc-containing mineral substance can effectively reduce the irritation of other raw material components to the skin. In addition, the synergistic effect between the film forming assistant and the film forming agent enhances the formation of the film, enhances the stability of a raw material system, can isolate oxygen in the air, stops the growth and reproduction of pathogenic bacteria, forms a grid shape on the surface of the skin of the protective film, and is beneficial to normal skin growth and repair.
The foregoing embodiments are merely illustrative of the principles and utilities of the present invention and are not intended to limit the invention. Any person skilled in the art can modify or change the above-mentioned embodiments without departing from the spirit and scope of the present invention. Accordingly, it is intended that all equivalent modifications or changes which can be made by those skilled in the art without departing from the spirit and technical spirit of the present invention be covered by the claims of the present invention.

Claims (8)

1. The liquid dressing for treating psoriasis is characterized by comprising the following raw materials in parts by weight: 1.0-5.0 parts of zinc pyrithione, 1.0-3.0 parts of zinc oxide, 1.0-6.0 parts of zinc-containing mineral substances, 0.1-1.0 part of menthol, 1.0-3.0 parts of ethanol, 0.1-1.0 part of borneol, 0.5-2.0 parts of parachlorometaxylenol, 10.0-20.0 parts of film-forming agent, 1.0-5.0 parts of film-forming assistant and 54.0-84.3 parts of purified water containing selenium.
2. The liquid dressing of claim 1, comprising the following raw materials in parts by weight: 3.0 parts of zinc pyrithione, 2.0 parts of zinc oxide, 6.0 parts of zinc-containing mineral substances, 0.5 part of menthol, 2.0 parts of ethanol, 0.5 part of borneol, 1.0 part of parachlorometaxylenol, 15.0 parts of film-forming agent, 3.0 parts of film-forming assistant and 67.0 parts of purified water containing selenium.
3. The fluid dressing of claim 1, wherein said zinc-containing mineral comprises zinc carbonate, zinc sulfate, zinc oxide, and zinc chloride.
4. The liquid dressing of claim 1, wherein said film former is formed from polyvinyl alcohol and polyvinyl pyrrolidone in a ratio of 1: 2 in mass ratio.
5. The liquid dressing of claim 1, wherein said film-forming aid is arachidyl glucoside.
6. The liquid dressing of claim 1, wherein the weight part ratio of the zinc pyrithione to the zinc-containing mineral is 1 (2-4).
7. A method of preparing a liquid dressing for use in the treatment of psoriasis as claimed in any of claims 1 to 6 comprising the steps of:
s1, weighing polyvinylpyrrolidone with a formula amount and selenium-containing water with a formula amount of 1/5, purifying, mixing, putting into a water bath heating pot, heating in a water bath, and fully dissolving until no granular sensation exists, thus obtaining polyvinylpyrrolidone solution;
s2, placing the rest selenium-containing purified water in a stirring pot, heating, adding zinc pyrithione, zinc oxide, zinc-containing mineral substances, polyvinyl alcohol, arachidyl glucoside, menthol, ethanol, borneol and parachlorometaxylenol in the formula amount, and stirring fully for later use;
s3, transferring the polyvinylpyrrolidone solution prepared in the step S1 to the stirrer in the step S2, fully stirring, and filling the finally obtained solution to obtain the required liquid dressing.
8. The method of preparing a liquid dressing for treating psoriasis as claimed in claim 7 wherein the purified water containing selenium of step S2 is heated to 40-60 ℃.
CN202110662447.5A 2021-06-15 2021-06-15 Liquid dressing for treating psoriasis Withdrawn CN113368132A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110662447.5A CN113368132A (en) 2021-06-15 2021-06-15 Liquid dressing for treating psoriasis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110662447.5A CN113368132A (en) 2021-06-15 2021-06-15 Liquid dressing for treating psoriasis

Publications (1)

Publication Number Publication Date
CN113368132A true CN113368132A (en) 2021-09-10

Family

ID=77574462

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110662447.5A Withdrawn CN113368132A (en) 2021-06-15 2021-06-15 Liquid dressing for treating psoriasis

Country Status (1)

Country Link
CN (1) CN113368132A (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4210633A (en) * 1978-10-20 1980-07-01 Eli Lilly And Company Flurandrenolide film formulation
US5747064A (en) * 1993-07-28 1998-05-05 Pfizer Inc. Psoriasis treatment
US6248370B1 (en) * 1997-07-24 2001-06-19 Leroy Harris Skin treatment and methods
US20180147213A1 (en) * 2015-05-06 2018-05-31 The Procter & Gamble Company Methods of cosmetically treating skin conditions with a cosmetic personal cleansing composition

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4210633A (en) * 1978-10-20 1980-07-01 Eli Lilly And Company Flurandrenolide film formulation
US5747064A (en) * 1993-07-28 1998-05-05 Pfizer Inc. Psoriasis treatment
US6248370B1 (en) * 1997-07-24 2001-06-19 Leroy Harris Skin treatment and methods
US20180147213A1 (en) * 2015-05-06 2018-05-31 The Procter & Gamble Company Methods of cosmetically treating skin conditions with a cosmetic personal cleansing composition

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHARLES E. CRUTCHFIELD III,等: "The highly effective use of topical zinc pyrithione in the treatment of psoriasis: a case report", 《DERMATOLOGY ONLINE JOURNAL》 *
杨志波: "《中成药临床应用指南 皮肤病分册》", 31 January 2017, 中国中医药出版社 *
钟静芬,等: "《表面活性剂在药学中的应用》", 29 February 1996, 人民卫生出版社 *

Similar Documents

Publication Publication Date Title
CN109044915B (en) Infant hip-protecting cream and preparation process thereof
WO1993011780A1 (en) Skin therapeutic mixture containing cold-processed aloe vera extract, with yellow sap and aloin removed
CN101129787A (en) Burn cream
CN110638727B (en) Infant hip-protecting composition and preparation method and application thereof
US20040131693A1 (en) Composition with a base of a therapeutically active compound, in particular honey, for the treatment of wounds
CN100455311C (en) Composition of Chinese traditional medicine in use for treating burn and scald, and product for resolving poxes, and preparation method
CN112451447A (en) Mild non-irritant efficient acne-removing composition and preparation method thereof
CN101658690A (en) Officinal volatile argyi leaf oil dressing and preparation method thereof
CN106619823A (en) Ointment for therapy of eczema and preparation method of same
CN111557877A (en) Toothpaste containing centella extract and preparation method thereof
WO2017080048A1 (en) Film spraying agent for superfical burns and preparation method therefor
WO2018137319A1 (en) Application of sarcococca vagans, chinese medicinal ointment for treating skin disease, preparation method and application thereof
CN102283899B (en) Traditional Chinese medicine external preparation and application thereof
KR100894439B1 (en) The composition for cosmetics having the prevention effect of atopy
CN113368132A (en) Liquid dressing for treating psoriasis
CN109731040A (en) A kind of wound remediation composition, preparation method and applications
CN109091596A (en) A kind of compound nursing gel for women and preparation method thereof
CN113456735B (en) Inactivated probiotic herbal gel and preparation method and application thereof
CN101332286B (en) Traditional Chinese medicine composition for treating skin disease and preparation method thereof
CN101181385A (en) Medicament for dispelling scar and preparation method thereof
CN112870269A (en) Natural galenical composition with antibacterial, bactericidal and eczema treating effects
CN101361938A (en) Kibe paste containing natural zingiber oil
CN111631991A (en) Private nursing lotion
CN110893218B (en) External traditional Chinese medicine preparation for treating infantile acute eczema and preparation method thereof
CN107308240A (en) One kind treats vaginitis and dermopathic active component and its production method

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20210910

WW01 Invention patent application withdrawn after publication